NCT06408688View on ClinicalTrials.gov

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

Immune checkpoint inhibitors plus Iscador® Qu.

Standard cancer treatment plus subcutaneous injection of mistletoe fermented extract (Iscador® Qu) as per the summary of product characteristics.

DRUG

Immune Checkpoint Inhibitors

Standard cancer treatment.

Trial Locations (4)

4031

RECRUITING

Universitätsspital Basel, Basel

4410

RECRUITING

Kantonsspital Baselland, Liestal

5404

RECRUITING

Kantosspital Baden AG, Baden

9016

RECRUITING

Tumor- und Brustzentrum Ostschweiz, Sankt Gallen

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER